Pharsight

Drugs that contain Deutetrabenazine

1. Austedo patents expiration

AUSTEDO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8524733 TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(6 years from now)

US9550780 TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733

(Pediatric)

TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Oct, 2031

(7 years from now)

US9296739 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

US9233959 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

US9814708 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

US11666566 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

US9233959

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US9296739

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US9550780

(Pediatric)

TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US9814708

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US11666566

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US11564917 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US10959996 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11357772 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11648244 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11446291 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US10959996

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11564917

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11648244

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11446291

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11357772

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11813232 TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Mar, 2038

(13 years from now)

US11179386 TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Mar, 2038

(13 years from now)

US11813232

(Pediatric)

TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Sep, 2038

(14 years from now)

US11179386

(Pediatric)

TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Sep, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-134) Apr 03, 2024
M(M-54) Jun 24, 2024
Pediatric Exclusivity(PED) Dec 24, 2024
New Indication(I-751) Aug 30, 2020
New Chemical Entity Exclusivity(NCE) Apr 03, 2022
Orphan Drug Exclusivity(ODE) Apr 03, 2024

NCE-1 date: 25 December, 2023

Market Authorisation Date: 03 April, 2017

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: TABLET;ORAL

How can I launch a generic of AUSTEDO before it's drug patent expiration?
More Information on Dosage

AUSTEDO family patents

Family Patents

2. Austedo Xr patents expiration

AUSTEDO XR Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8524733 TEVA Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(6 years from now)

US9550780 TEVA Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733

(Pediatric)

TEVA Benzoquinoline inhibitors of vesicular monoamine transporter 2
Oct, 2031

(7 years from now)

US9550780

(Pediatric)

TEVA Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US11564917 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11648244 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11446291 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11357772 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US10959996 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US10959996

(Pediatric)

TEVA Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11564917

(Pediatric)

TEVA Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11446291

(Pediatric)

TEVA Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11357772

(Pediatric)

TEVA Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11648244

(Pediatric)

TEVA Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11813232 TEVA Analogs of deutetrabenazine, their preparation and use
Mar, 2038

(13 years from now)

US11179386 TEVA Analogs of deutetrabenazine, their preparation and use
Mar, 2038

(13 years from now)

US11813232

(Pediatric)

TEVA Analogs of deutetrabenazine, their preparation and use
Sep, 2038

(14 years from now)

US11179386

(Pediatric)

TEVA Analogs of deutetrabenazine, their preparation and use
Sep, 2038

(14 years from now)

US11311488 TEVA Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
Jun, 2041

(17 years from now)

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

AUSTEDO XR family patents

Family Patents